- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/19 - Rubella virus
Patent holdings for IPC class C07K 14/19
Total number of patents in this class: 24
10-year publication summary
|
2
|
0
|
2
|
1
|
1
|
3
|
0
|
1
|
1
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| F. Hoffmann-La Roche AG | 7835 |
3 |
| Futuragene Israel Ltd. | 27 |
2 |
| Roche Diagnostics GmbH | 2714 |
1 |
| The Regents of the University of California | 20534 |
1 |
| Agenus Inc. | 153 |
1 |
| Children's Hospital Los Angeles | 117 |
1 |
| Consejo Superior de Investigaciones Cientificas (csic) | 1430 |
1 |
| Fundacao Oswaldo Cruz | 106 |
1 |
| Fundacion Pedro Barrie de La Maza, Conde de Fenosa | 6 |
1 |
| Instituto de Biologia Molecular do Parana-ibmp | 7 |
1 |
| The James Hutton Institute | 29 |
1 |
| Morehouse School of Medicine | 157 |
1 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2968 |
1 |
| Universidade de Santiago de Compostela | 329 |
1 |
| Universidade Federal do Parana-ufpr | 4 |
1 |
| The University of British Columbia | 1529 |
1 |
| Virginia Commonwealth University | 650 |
1 |
| Prime bio, Inc | 12 |
1 |
| Trim-edicine, Inc. | 6 |
1 |
| Simurx, Inc. | 3 |
1 |
| Other owners | 1 |